Revenue

From biopharma to webcomics, shareholder lawsuits reveal the perils of misleading investors. A look at four companies facing legal and financial fallout.

Focus Financial Partners names growth architect Adam Birenbaum its next CEO, signaling a strategic shift toward deeper integration and accelerated expansion.

Jiuzi Holdings announced a $4M offering, tanking its stock. Then, news of a $1B crypto funding plan sent it soaring. A deep dive into a high-stakes pivot.

HCIactive's SmartBenefits.ai promises AI-powered clarity for your health plan, but a major data breach reveals the high-stakes risks of this new frontier.

Huntington Bank opens a South Euclid branch, blending community focus with an aggressive M&A strategy aiming to make it a top 10 U.S. bank.

Ripple just secured a federal bank charter for its stablecoin, RLUSD. This landmark move, enabled by the GENIUS Act, could redefine trust in crypto.

Updated trial results for Lilly's Inluriyo-Verzenio combo extend life without chemo, positioning the firm for dominance in a competitive oncology market.

Alamo Group's acquisition of Petersen Industries for $166.5M isn't just another deal. It's a strategic move to dominate the waste management equipment market.

A top Forbes ranking is impressive, but HealthWell Foundation's 100% fundraising efficiency reveals a new benchmark for non-profit impact. Here's how.

Global crypto exchange HTX gains a crucial regulatory nod in Pakistan, paving the way for licensed operations in one of the world's fastest-growing digital asset hubs.

Amid a $2.37B buyout, Weiss Asset Management's increased stake in Avadel Pharma raises questions. Is it a vote of confidence or a strategic power play?

Greenway Technologies is leaving the lab. A new deal with a Native-owned firm aims to turn stranded gas into gold, but can the micro-plant economics work?

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

Hedge fund Balyasny Asset Management builds a 1.72% stake in JTC plc, signaling high-stakes maneuvering in the £2.3 billion takeover saga.

A routine filing by hedge fund Balyasny Asset Management may have just put Avadel Pharmaceuticals in the M&A spotlight. Here's what the signal means.

A new book arms working mothers with legal secrets HR won’t share, forcing businesses to rethink their strategic approach to talent and compliance.

Boston's Weiss Asset Management reveals a strategic 4.17% derivative stake in International Personal Finance as a takeover deadline looms.

This REIT's stock is worth millions, but it claims its apartments are worth much more. Can a bold strategic review unlock this hidden value for investors?

A deep dive into Perma-Pipe's record-breaking quarter, revealing a strategy of regional dominance and savvy diversification into high-growth tech sectors.

When a trusted professional evades over $1 million in taxes, the impact goes beyond the courtroom, shaking public trust and starving community services.